Document is current
Any future updates will be listed below
-
Authors
Arteaga-Vazquez, Leo J.
Sepulveda, Hugo
Villalobos Reveles, Bruno
Suzuki, Kazumasa
Kalunian, Kenneth C.
Ay, Ferhat
Boothby, Mark R.
Rao, Anjana
-
Funding
Funding for this research was provided by:
National Institutes of Health (R35 CA210043, R35 CA210043, R35 CA210043, R35 CA210043, R35 CA210043)
National Institutes of Health, United States (R01 CA247500, R01 CA247500, R01 CA247500, R01 CA247500, R35 GM128938, R01 CA247500)
Pew Latin-American Fellows Program from The Pew Charitable Trusts
Fellowship from the California Institute for Regenerative Medicine
Tulley and Rickey Families SPARK Award for Innovations in Immunology from the La Jolla Institute for Immunology
Wolfe Family Lupus Center of Excellence at UC San Diego Fund
Development Funds of the Pathology-Microbiology-Immunology Department, Vanderbilt University Medical Center
- License Information
-
More Information
Article History
Received: 7 August 2025
Accepted: 8 September 2025
First Online: 3 November 2025
Declarations
:
: A.R. is a member of the scientific advisory board of biomodal (formerly Cambridge EpiGenetix, CEGX), Cambridge, UK. All other authors declare no competing interests.
: Not applicable. No human subjects were used in this study, which is a reanalysis of existing publicly available datasets.
: Not applicable. This study is a reanalysis of existing publicly available datasets.
